- Home
- HIVE vs VSTM Comparison
HIVE vs VSTM Comparison
Compare HIVE & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIVE | VSTM |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.6M | 470.7M |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HIVE | VSTM |
|---|---|---|
| Price | $2.86 | $5.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $6.44 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 17.6M | 1.9M |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $169.51 | $282.64 |
| Revenue Next Year | $39.45 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $1.60 | $4.01 |
| 52 Week High | $7.84 | $11.25 |
Technical Indicators
Market Signals| Indicator | HIVE | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 47.31 |
| Support Level | $2.63 | $5.38 |
| Resistance Level | $3.07 | $6.79 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 85.12 | 34.17 |
Price Performance
Historical ComparisonAbout HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.